Clinical Trial Update: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating selinexor for intermediate- and high-risk smoldering multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Selinexor (Xpovio) (Selinexor)

Snippet

Sponsor: University of Rochester | Conditions: Smoldering Multiple Myeloma | Phase 2 | Status: RECRUITING